|
Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). |
|
|
|
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Merck |
|
|
Consulting or Advisory Role - ARMO Biosciences; Celgene; Incyte; Merrimack; Oncogenex; Threshold Pharmaceuticals |
Research Funding - Aduro Biotech (Inst); Celgene (Inst); ImClone Systems (Inst); Infinity Pharmaceuticals (Inst); PharmaEngine (Inst); PRISM BioLab (Inst); Seagen (Inst) |
|
|
Consulting or Advisory Role - Amgen; Sirtex Medical; Taiho Pharmaceutical |
Speakers' Bureau - Genentech |
Research Funding - Biomarin (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst) |
Travel, Accommodations, Expenses - Amgen; Genentech; Lilly |
|
|
Stock and Other Ownership Interests - Abbvie; Amgen; Johnson & Johnson |
|
Consulting or Advisory Role - Halozyme; Taiho Pharmaceutical |
Research Funding - Aduro Biotech; Clovis Oncology; FibroGen; Immunomedics; Incyte; OncoMed; Theranostics Health |
|
|
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Bayer; Celgene; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; MedImmune; Merck; Plexxikon; Verastem |
Research Funding - AB Science; Aduro Biotech; Astellas Pharma; AstraZeneca; Bayer; Celgene; GlaxoSmithKline; Incyte; MedImmune; Merck; Verastem |
Expert Testimony - Aduro Biotech |
|
|
Honoraria - Merrimack; Pfizer |
Consulting or Advisory Role - Merrimack; pfizer |
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); CTI (Inst); EMD Serono (Inst); Halozyme (Inst); Merrimack (Inst); Newlink Genetics (Inst); OncoMed (Inst); pfizer (Inst); Precision Therapeutics (Inst); Prometheus (Inst) |
Travel, Accommodations, Expenses - Axis Pharma |
|
|
|
|
|
Stock and Other Ownership Interests - PhytoChem |
Honoraria - Astellas Pharma; Bayer; Boehringer Ingelheim; EMD Serono; Etubics; Genentech/Roche; Ipsen; Lexicon; Merrimack; Novartis; Onyx; Regeneron; Sanofi; Taiho Pharmaceutical |
Speakers' Bureau - Celgene; Genentech/Roche; Novartis; Taiho Pharmaceutical |
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Merck (Inst); Onyx (Inst); Precision Biologics (Inst) |
|
|
Research Funding - Aduro Biotech (Inst) |
|
|
Honoraria - Celgene; Lilly; Merrimack |
Consulting or Advisory Role - Celgene; Merrimack |
Research Funding - Abbvie; Bayer; Celgene; Genentech/Roche; Lilly; Millennium |
|
|
No Relationships to Disclose |
|
|
Employment - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
|
|
Employment - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech; Bavarian Nordic; Exelixis |
|
|
No Relationships to Disclose |
|
|
Employment - Aduro Biotech |
Leadership - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
Consulting or Advisory Role - Turnstone Bio |
Patents, Royalties, Other Intellectual Property - Aduro Biotech |
|
|
Employment - Aduro Biotech |
Leadership - Aduro Biotech |
Stock and Other Ownership Interests - Aduro Biotech |
Patents, Royalties, Other Intellectual Property - Aduro Biotech |
|
|
Consulting or Advisory Role - Aduro Biotech; MedImmune; Vaccinex (Inst) |
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Roche |
Patents, Royalties, Other Intellectual Property - Aduro Biotech |
Travel, Accommodations, Expenses - Janssen |